https://www.theguardian.com/world/2022/jul/31/new-york-city-monkeypox-public-health-emergency
Launch of research-use-only adenovirus F41 assay
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children
Paris, France and Camberley, UK - 28 July 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a research-use-only (RUO) polymerase chain reaction (PCR) assay for the detection of adenovirus F41, in response to recent cases of acute hepatitis in children. This launch expands Novacyt's genesig® real-time PCR diagnostic product portfolio and is in line with the Company's strategy to maintain its position as a global first responder in infectious diseases.
Adenoviruses are a large group of viruses divided into several species and subtypes. They are the cause of several illnesses, usually exhibiting as colds or flu-like illness, which may also cause gastrointestinal symptoms such as diarrhoea. Adenoviruses are primarily spread via respiratory droplets; however, they can also be spread by faecal routes. Ongoing investigations, particularly in the UK, have identified adenovirus infection in children, and in particular, adenovirus F41 in several cases.
This assay has been developed in two forms, genesig® Advanced and genesig® Easy, designed for in vitro detection of adenovirus species F serotype 41 genomes, without detecting any closely related adenovirus sequences. Novacyt's genesig® Advanced assay is configured for use with any open test platform, including Novacyt's MyGo instruments, the genesig® Easy assay is suitable for use on the Company's q16 and q32 instruments.
Novacyt, through its specialist bioinformatics surveillance expertise, continually tracks the changing pathology of diseases worldwide, and will regularly review the detection profile of assays, ensuring that new versions are developed if necessary.
David Allmond, Chief Executive Officer of Novacyt, commented:
"Our RUO adenovirus F41 assay has been developed in response to recent cases of acute hepatitis in children to support research efforts in determining the cause of this severe disease. The launch of this new assay, as well as our recent assay for the detection of the Monkeypox virus, subsequently declared a global health emergency by the WHO, reinforce Novacyt's position as a global first responder, as well as our commitment to expanding our portfolio in infectious diseases, both in line with our stated strategy. Our extensive leading RUO portfolio consists of over 850 products, spanning veterinary, food, environment, and human health research. The portfolio is a key part of our core business and serves as an innovation engine for the Company as we transition beyond the Covid-19 pandemic."
https://metro.co.uk/2022/07/23/who-declares-monkeypox-outbreak-a-global-health-emergency-17055470/
@Wilson - Thanks for your post earlier but didn't see their actual comment as I blocked them weeks ago!
https://www.msn.com/en-gb/health/medical/new-york-records-first-us-case-of-polio-in-decades/ar-AAZPwTO?ocid=msedgntp&cvid=279c27307e5540c6a9ae2d561c8e6a59
https://edition.cnn.com/2022/07/21/politics/joe-biden-covid-19/index.html
Brent
Hit the nail on the head - why would any future investors buy into this business after reading some of the posts that continually criticise- I not happy with current performance but it still doesn’t encourage me to press the self destruct button!
https://news.sky.com/story/the-perfect-petri-dish-animal-to-human-disease-outbreaks-rise-by-more-than-60-in-africa-12652036
DA spoke about "Zoonoses" as part of the corporate strategy - also reminded investors that "Novacyt has a track record as a global first responder"
2009 H1N1 Swine Flu
2014 EBOLA
2017 ZIKA
2020 COVID19
Lets hope they are truly on it and it's not too long before we see what Novacyt has next in its tool kit and it won't much longer before the LTH get some reward for sticking with it and they do continue to be a global first responder!
Partnership case studies
Company A specialises in the development of high precision liquid handling robotics and software for life science research. Novacyt has partnered with them to define, develop, and deliver novel automation solutions for molecular IVDs. The partnership resulted in an accelerated product development pathway and both companies are benefitting as Novacyt leverages its global commercial reach to deliver a platform technology delivering new decentralised workflow solutions to the market.
Company B has partnered with Novacyt in response to the COVID-19 pandemic, with the companies collaborating on products, sold under the Novacyt brand. Novacyt has supported Company B in demonstrating product quality and performance in clinical evaluations and helped them access global markets utilising Novacyt’s expertise in registration and approval of IVD products. Novacyt continues to support Company B in product development and optimisation.
Company C has developed a novel sensor and portable reader for the detection of small organic molecules. Novacyt has partnered with the company to re-purpose the technology as a novel biosensor that can be utilised as an IVD platform. Partnering with Novacyt has helped them develop products and access the global IVD market.
Also tonight's Tweet
https://twitter.com/NovacytGroup/status/1547250508850774018/photo/1
Kilkenny's earlier post - WHO link - Have had a quick read through and lifted the extract below
WHO Director-General's opening remarks at the COVID-19 media briefing– 12 July 2022
"The WHO Committee made a series of recommendations with several that I want to focus on".
New waves of the virus demonstrate again that the COVID-19 is nowhere near over.
As the virus pushes at us, we must push back.
We’re in a much better position than at the beginning of the pandemic.
Of course, there’s been a lot of progress.
We have safe and effective tools that prevent infections, hospitalizations and deaths.
However, we should not take them for granted.
As G-20 finance ministers meet next week, it is critical that governments around the world finance WHO and the ACT-Accelerator to ensure the equitable distribution of health tools.
As transmission and hospitalisations rise, governments must also deploy tried and tested measures like masking, improved ventilation and test and treat protocols.
I urge governments to regularly review and adjust their COVID-19 response plans based on the current epidemiology and also the potential for new variants to appear.
Governments should also work to reverse the reduction in surveillance, testing and sequencing, and share anti-virals effectively.
Vaccines have saved millions of lives and it’s important for governments to focus on boosting those most at-risk communities, finding the unvaccinated so as to build up the wall of immunity toward the 70 percent vaccination target.
Planning and tackling COVID-19 should also go hand-in-hand with vaccinating for killer diseases like measles, pneumonia and diarrhoea.
It’s not a question of either/or, it’s possible to do both.
And new vaccines, including HPV and malaria, should continue to be introduced.
Today, WHO released the first-ever report on vaccines in development to prevent infections caused by antimicrobial resistant bacterial pathogens.
The report examines some of the challenges facing vaccine development and proposes disruptive approaches to nurture innovation in a space that has been severely neglect
-----------------------------------------------------------------------
I then had another look at the Full Year Results Novacyt presentation 28th April to see if there were any synergies between the above WHO recommendations that may indicate if the WHO partnership might continue after July 2022?????
I know often when you re-visit presentation/documents you can sometimes pick up on things you missed first time around!
Have re-attached if anyone is interested.
https://www.investormeetcompany.com/investor/meeting/full-year-results-29
Thanks to Kilkenny's Post
Hope this puts us in a good place for a share of the £2 Billion contract!
https://www.bioindustry.org/static/517ea7e6-e6b5-425d-b8f62c7aba988a1e/DIT-Genomics-Spotlight-Leading-Innovations-2022.pdf
https://www.reuters.com/markets/deals/astrazeneca-buy-oncology-firm-teneotwo-up-127-bln-2022-07-05/